Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Should investors be worried about weakness in the company's ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

It's shaping up to be a tough period for Eli Lilly and Company , which a week ago released some disappointing third-quarter ...

We recently compiled a list of the 10 Best S&P 500 Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

But earnings in the new range would still wind up being more than twice what the company registered for 2023. Shares of Indianapolis-based Eli Lilly and Co. were down 6%, or $57.02, to $846.56 in ...

U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...